Navigant Pathogen Inactivation System Catching Up With Cerus, Vitex
This article was originally published in The Gray Sheet
Executive Summary
Navigant Biotechnologies is dedicating $10 mil. in 2004 to the development of its Mirasol riboflavin-based pathogen reduction technology (PRT) for platelets and red blood cells
You may also be interested in...
Gambro Sale Of U.S. Dialysis Services Leaves $2 Bil. For Possible Acquisitions
Gambro's plan to refocus on its core renal and blood bank product offerings by divesting its U.S. dialysis services business provides about $2 bil. for potential acquisitions in related fields
Gambro Sale Of U.S. Dialysis Services Leaves $2 Bil. For Possible Acquisitions
Gambro's plan to refocus on its core renal and blood bank product offerings by divesting its U.S. dialysis services business provides about $2 bil. for potential acquisitions in related fields
People In Brief
Cerus brings in new blood: William Dawson joins firm Aug. 9 as chief financial officer. Previously, Dawson served as CFO at biopharmaceutical firm Dynavax Technologies Corp., where he spearheaded the creation and $61 mil. IPO of Dynavax Asia. Dawson replaces Gregory Schafer, who had been Cerus' CFO since 1999. Cerus recently inked a marketing and distribution agreement with BioOne Corp for Asian commercialization of its Intercept blood system for pathogen inactivation. The Concord, Calif.-based concern's efforts to bring Intercept to the U.S. market encountered delays when it chose to halt its Phase III trial for the red blood cell pathogen reduction program after two patients developed antibodies (1"The Gray Sheet" March 29, 2004, p. 14)...